LumiraDx Limited (LMDX)
| Previous close | 0.0160 |
| Open | 0.0211 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0151 - 0.0282 |
| 52-week range | 0.0151 - 0.0282 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq’s Listing Qualifications Departm
ZacksRoche (RHHBY) to Acquire LumiraDx's Point of Care Technology
Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.
- Reuters
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million. Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction is expected to close by mid-2024, after which the acquired segment will become a part of Roche's diagnostics unit, the drugmaker said.
